Patients with advanced ovarian cancer can choose to use Bevacizumab in first-line treatment or in the stage of ovarian cancer recurrence.
Patients with advanced ovarian cancer can use bevacizumab in combination with chemotherapy at the time of first-line treatment, and bevacizumab is used as maintenance therapy after the completion of chemotherapy. Studies have proved that the above regimen can prolong the median progression-free survival of patients with advanced ovarian cancer.
Stage of recurrent ovarian cancer: Studies have shown that the regimen of bevacizumab combined with paclitaxel plus carboplatin has significant efficacy in the treatment of recurrent ovarian cancer, and this regimen not only improves the near-term efficacy of patients with recurrent ovarian cancer, but also improves the long-term survival of patients, and it does not increase the number of adverse reactions.
In the NCCN guidelines, the panel considered bevacizumab to be the first choice for patients with recurrent ovarian cancer, especially those with combined ascites, and bevacizumab was effective in both platinum-sensitive or platinum-resistant recurrent patients.
Platinum-sensitive recurrent epithelial ovarian cancer can be treated with bevacizumab in combination with carboplatin plus gemcitabine, carboplatin plus doxorubicin liposome or carboplatin plus paclitaxel; individual drugs of targeted agents can also be used for treatment, such as bevacizumab, niraparib, olaparib and lukaparnib.
Patients with advanced ovarian cancer need to strictly follow the doctor’s instruction to use targeted drugs.